Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unrescetable Hepatocellular Carcinoma”

2 trials

Showing 2 of 2 results

Testing effectiveness (Phase 2)UnknownNCT05864755
What this trial is testing

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Who this might be right for
Unrescetable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05821361
What this trial is testing

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Who this might be right for
Unrescetable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation